Mazen Noureddin

1 month ago | hcplive.com | Jeff McIntyre |Mazen Noureddin |Juan Pablo Arab

On March 14, 2024, the US Food and Drug Administration (FDA) made history when it granted accelerated approval to Madrigal Pharmaceuticals’ resmetirom (Rezdiffra), making it the first and only treatment for noncirrhotic nonalcoholic steatohepatitis (NASH), now known as metabolic dysfunction-associated steatohepatitis (MASH). One year later, resmetirom’s impact on clinical practice and patient care continues to evolve.

1 month ago | hcplive.com | Jeff McIntyre |Mazen Noureddin |Juan Pablo Arab

On March 14, 2024, the US Food and Drug Administration (FDA) made history when it granted accelerated approval to Madrigal Pharmaceuticals’ resmetirom (Rezdiffra), making it the first and only treatment for noncirrhotic nonalcoholic steatohepatitis (NASH), now known as metabolic dysfunction-associated steatohepatitis (MASH). One year later, resmetirom’s impact on clinical practice and patient care continues to evolve.